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A new ligand H3L, with internal compartments for allocating 3d metal ions and external 
donors to bind 4f ions, was synthesized and completely characterized. R action of H3L with 
zinc(II) and gadolinium(III) salts allows isolating the heteronuclear complex 
{[ZnGd(HL)(NO3)(OAc)(CH3OH)](NO3)} ·6H2O (1·6H2O). The ability of 1·6H2O to act as a 
magnetic resonance imaging (MRI) contrast agent was ev luated and this study shows that 
both the transversal and longitudinal relaxivities are quite high but the T1/T2 ratio of 7.9 
indicates that it could have even greater potential as a T2 contrast agent.  
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Introduction 
The application of gadolinium(III) complexes as contrast agents (CAs) in magnetic resonance 
imaging requires stable complexation of the metal ion under physiological conditions to avoid 
the release of the toxic free Gd(III).1 Several pathways leading to the potential dissociati n of 
Gd3+ complexes in vivo have been identified: 1) acid-catalyzed dissociation; 2) dissociation 
catalyzed by endogenous metal ions such as Zn2+ a d Cu2+ and 3) dissociation assisted by 
endogenous ligands like citrate, phosphate or bicaronate. Accordingly, the continuous search 
for new CAs with increasing stability and relaxivities respect to the commercial ones is still a 
challenge. In this sense, it should be noted that several gadolinium CAs have shown not only 
to be stables in the presence of ZnII but to improve their relaxation time.2,3  
With these considerations in mind, in this work we prepare the new ligand H3L 
(Scheme 1), with predesigned compartments to allocate 3d and 4f ions, with the aim of 
isolating a ZnGd heretonuclear complex and evaluate its ability to act as CA for MRI. 
Results and discussion 
H3L was obtained according to Scheme 1 
 
Scheme 1 
Analytical and spectroscopic data corroborate the isolation of the desired compound, 
with high purity, and unequivocally validate the formation of the imine groups and the 
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imidazolidine ring. In this way, the H4 and H17 protons (Fig. 1) appear as singlets in the 
1H NMR spectrum at 3.83 and 8.16 ppm, respectively, and the IR spectrum shows an intense 
band at 1633 cm-1, which can be assigned to ν(C=N).  
 
Fig. 1. 1H NMR spectrum of H3L in CDCl3 
H3L reacts with Zn(OAc)2·2H2O and Gd(NO3)3·6H2O in 1:1:1 molar ratio to yield the 
heteronuclear complex {[ZnGd(HL)(NO3)(OAc)(CH3OH)](NO3)} (1), as shown in Scheme 2, 
which precipitates as the hexahydrate 1·6H2O.  
 
Scheme 2. Reaction scheme for isolating 1. 
The analytical, spectroscopic and X-ray diffraction characterization of 1·6H2O agrees 
with the structure proposed in Scheme 2. Thus, the comparison of the IR spectrum of the 
complex with that of the free ligand shows that the band assigned to ν(C=N) splits into two 
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new bands at 1636 and 1648 cm-1, due to the loss of symmetry of the ligand in the complex. 
In addition, new bands are observed at 1556 cm-1, assigned to ν(COO-), and at 1300 and 
1285 cm-1, assigned to NO3
- vibrations, in agreement with the presence of the ac tate and 
nitrate donors in the metal complex.4 Finally, it is possible to observe a broad band centred at 
3264 cm-1, which indicates the presence of water and methanol in the compound.  
Several attempts to grow single crystals of 1·6H2O were unsuccessful and only allowed 
to obtain small single crystals. Thus, X-ray diffraction studies were not of enough quality to 
solve the structure but they let to know the unit cell parameters, which are the following ones: 
crystal system: monoclinic; a = 10.82(3), b = 16.29(5), c = 26.67(7) Å; β = 97.37(6) º; 
V=4659(37) Å3. These parameters are very similar to those found for a ZnDy complex with 
the same ligand5 and, therefore, the structure should be very akin nd should agree with the 
proposed one in Scheme 2. 
The potentiality of 1·6H2O as a MRI contrast agent was evaluated. Thus, longitudinal R1 
and transversal R2 relaxivities were measured. The R1 value of 4.90 mM
-1s-1 is comparable 
with those found for other commercial agents,6 and, therefore, it could be said that 1·6H2O 
should be a good T1 contrast agent. Nevertheless, the R2 value is 38.63 mM
-1s-1, and, 
therefore, the T1/T2 (R2/R1) ratio is 7.9, value that strongly differs from 1. As a consequence, 
this precludes the use of 1·6H2O as a positive MRI contrast.
7 However, the R2 value is also 
quite large and the T1/T2 ratio is higher than 6, which is a condition for a species being used as 
a T2 contrast agent. Accordingly, it seems that this heteronuclear ZnGd complex could be a 
candidate as a negative MRI contrast, in spite of usual T2 agents are based, for example, on 
magnetic iron oxide nanoparticles.8 
The potential of the GdZn system to serve as contrast agent was also demonstrated using 
in vitro MRI on tube phantoms. The MRI experiments were conducted using a reference 
without complex (at 12 o’clock in phantoms, see Fig. 2) and six different increasing 
concentrations (clockwise) of the synthesized complex (0.05, 0.2, 0.5, 1, 1.2 and 1.5 mM).  
 
Fig. 2. T1-weighted (left) and T2-weighted (right) MR images for 1·6H2O 
The T1-weighted phantom shows that a bright image can be gradually obtained by 
increasing the complex concentration up to 0.5 mM; in contrast, at higher concentrations the 
image becomes darker. On the other hand, the T1-weighted phantom darkens as the 
concentration increases. Accordingly, this seems to indicate that, as previously anticipated on 
the basis of the T1/T2 ratio, 1·6H2O has a better performance as a T2 contrast agent.  
Conclusions 
The new H3L ligand, with differentiated compartments for 3d and 4f metal ions, has 
been satisfactorily isolated and characterized. Theligand yields the heteronuclear ZnGd 
complex {[ZnGd(HL)(NO3)(OAc)(CH3OH)](NO3)} ·6H2O. This complex shows longitudinal 
relaxivities comparable to those of commercial T1 CAs but the T1/T2 ratio considerable higher 
than 1 indicates that it is not a good candidate for being used as a positive MRI contrast agent. 
Nevertheless, the relatively high transversal relaxivity R2 and the T1/T2 ratio higher than 6 
suggest a better performance as magnetic negative imaging contrast agent. These results are 
validated by in vitro MRI phamtons. 
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Experimental 
Synthesis of H3L  
H3L was isolated as follows: to a solution of 5-bromo-2-hydroxybenzaldehyde (1.386 g, 6 
mmol) in methanol (40 mL), triethylentetramine (0.292 g, 2 mmol). The solution was stirred 
in air for 4 h. and a yellow solid precipitated, being subsequently filtered off and dried in air 
1.2 g (76%). MW: 785.32 gmol-1. M.P.: 200-202 ºC. Elemental analysis: experimental: 
C 45.89, N 6.96, H 4.25%; calcd. for C30H33N4O6Br3: C 45.88, N 7.13, H 4.23. IR spectrum 
(ATR, ν/cm-1): 1633 (C=N). 1H NMR (250 MHz, CDCl3, δ  ppm): 2.65-2.74 (m, 4H, 
2H1+2H2); 2.93-3.01 (m, 2H, 2H2); 3.43-3.38 (m, 2H, 2 1); 3.61 (t, 4H, 4H3); 3.83 (s, 1H, 
H17); 3.86 (s, 3H, CH3); 3.89 (s, 6H, 2CH3); 6.77 (s, 1H, H11); 6.95-7.01 (m, 5H, 2H6 + 2H8 
+ H13); 8.16 (s, 2H, 2H4); 10.86 (s, 1H, OH); 13.78 (s, 2H, 2OH). RMN-1H (250 MHz, 
DMSO-d6, δ ppm): 2.57-1.69, 2.71-2.80 (m, 6H, 2H1 + 4H2); 3.27-3.34 (m, 2H, 2H1); 3.53-
3.65 (m, 4H, 4H3); 3.71 (s, 3H, CH3); 3.77 (s, 6H, 2CH3); 4.09 (s, 1H, H17); 6.94 (s, 1H), 
6.97 (s, 1H) (H11 + H13); 7.06 (s, 2H), 7.18 (s, 2H) (2H6 + 2H8); 8.34 (s, 2H, 2H4).  
Synthesis of {[ZnGa(HL)(NO 3)(OAc)(CH3OH)](NO 3)}·6H2O (1·6H2O) 
To a CHCl3 (5 mL) solution of H3L (0.074 g, 0.094 mmol), Zn(OAc)2·2H2O (0.021 g, 0.094 
mmol) was added. Then, to the resultant yellow solution Gd(NO3)3·6H2O (0.042, 0.094 
mmol) and 5 mL of methanol were added. The mixture was stirred at room temperature for 
2 h and a finely divided yellow powder is obtained. The solid is separated by centrifugation 
and dried in air. 072 g (58%). MW: 1329.12 gmol-1. Elemental analysis: experimental: 
C 29.35, N 6.54, H 3.24%; calcd. For ZnGdC33H50N6O21Br3: C 29.82, N 6.32, H 3.79%. IR 
spectrum (ATR, ν/cm-1): 1636, 1648 (C=N); 1557 (COO-); 1285, 1300 (NO3
-); 3264 (OH). 
MRI measurements 
MRI studies at high magnetic field were conducted on a 9.4 T MR system (Bruker Biospin, 
Ettlingen, Germany) with 440 mT/m gradients. A quadrature radio-frequency transmit-receive 
resonator was used for data acquisition. T2-weighted images were acquired using a multi slice 
multi echo sequence of 11.32 ms echo time, 3000 ms repetition time, 16 echoes, 14 slices, 1 
average, FOV of 7.5 cm X 7.5 cm and matrix size of 300 X 300. T1-weighted images were 
acquired using a RARE-VTR sequence of 10.81 ms echotime, rare factor 4, repetition times 
of 3000 ms, 3235 ms, 3491 ms, 3770 ms, 4078 ms, 4422 ms, 4810 ms, 5256 ms, 5779 ms, 
6414 ms, 7221 ms, 8327 ms, 10098 ms and 15000 ms. 14 slices, 1 average, FOV of 7.5 cm X 
7.5 cm and a matrix size of 300 X 300. Post-processing was performed using ImageJ software 
(Rasband, W. NIH).  
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